Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot-Reference-Cited by-同舟云学术

Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot

Published:2004-02 Issue:2 Volume:2 Page:234-241
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Alexander J. H.,Dyke C. K.,Yang H.,Becker R. C.,Hasselblad V.,Zillman L. A.,Kleiman N. S.,Hochman J. S.,Berger P. B.,Cohen E. A.,Lincoff A. M.,Saint-Jacques H.,Chetcuti S.,Burton J. R.,Buergler J. M.,Spence F. P.,Shimoto Y.,Robertson T. L.,Kunitada S.,Bovill E. G.,Armstrong P. W.,Harrington R. A.,

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1538-7933.2004.00594.x/fullpdf

Reference24 articles.

1. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)31This document was approved by the American College of Cardiology Board of Trustees in April 2001 and by the American Heart Association Science Advisory and Coordinating Committee in March 2001.32When citing this document, the American College of Cardiology and the American Heart Association would appreciate the following citation format: Smith SC, Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO. ACC/AHA guidelines for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 2001;37:2239i–lxvi.33This document is available on the ACC Web site at www.acc.organd the AHA Web site at www.americanheart.org(ask for reprint no. 71-0206). To obtain a reprint of the shorter version (executive summary and summary of recommendations) to be published in the June 15, 2001 issue of the Journal of the American College of Cardiology and the June 19, 2001 issue of Circulation for $5 each, call 800-253-4636 (US only) or write the American College of Cardiology, Educational Services, 9111 Old Georgetown Road, Bethesda, MD 20814-1699. To purchase additional reprints up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1,000 or more copies, call 214-706-1466, fax 214-691-6342, or E-mail: pubauth@heart.org(ask for reprint no. 71-0205).

2. Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention

3. Low-Molecular-Weight Heparin

4. Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention

5. A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary anticoagulation therapy in patients undergoing percutaneous intervention;Expert Review of Cardiovascular Therapy;2014-02-10

2. New Antithrombotic Drugs;Chest;2012-02

3. Is there Evidence to Support the Use of Direct Factor Xa Inhibitors in Coronary Artery Disease?;Reviews on Recent Clinical Trials;2011-05-01

4. Anticoagulants;Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease;2011

5. First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention;Circulation;2010-08-10